Compare Equinix Inc (EQIX) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Equinix (EQIX) trades at $1,026.06, down 0.55% on the day, amid a bearish technical signal. The stock shows strong fundamentals with revenue growth from $9.22B in 2025 to a projected $9.8B in 2026 and a net income margin of 15.63%. Recent earnings saw a mix of beats and misses, with Q2 2026 EPS of $4.83 exceeding expectations. Analyst sentiment remains overwhelmingly positive with a 75.47% buy rating and a consensus price target of $1,250.

The outlook for EQIX is supported by robust AI-driven data center demand and a $5B-$7B annual expansion plan, but risks include high valuation multiples (P/E of 65.07) and significant capital expenditures leading to negative cash flow. The stock presents a growth opportunity tied to digital infrastructure trends, though investors should weigh elevated debt levels and execution risks against long-term potential.

INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.

The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.